Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

After offering some brief insight into the operations of Skyline Medical, Schwartz turned his attention toward TumorGenesis. “TumorGenesis is an interesting company. The whole purpose of it was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors,” he stated in the interview. “They have developed the first one, which is ovarian cancer, and the results of this are that this media, which, as I said, replicates the body, fools the tumor into thinking it’s still in the body. Its reactions are very, very similar to what it would have done had it been in the body. Now, the next step is to get it positioned to manufacturers and getting the kits out so people can use it. That’s coming along handsomely. It’ll take a little time to get all this put in place, but the optimism is there, and the results are wonderful. We’re very excited.”

Share | Download